Joyce F. Liu

ORCID: 0000-0003-3888-3972 · 3 papers in corpus
case-report 2024
Successful treatment of stage IVB ovarian carcinosarcoma with PARP Inhibitor: A case report
Gynecologic oncology reports ·doi:10.1016/j.gore.2024.101322

•Ovarian carcinosarcoma is a rare ovarian cancer histology that has limited treatment options.•In this study, we present an unusual association between carcinosarcoma and a STIC lesion.•In select patients with carcinosarcoma, PARP inhibitio…

nonrandomized-trial 2021
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
·doi:10.1200/jco.2021.39.15_suppl.tps5609

TPS5609 Background: Despite significant strides in understanding the molecular pathogenesis of EC, there remain few effective therapies for recurrent disease. Deeper insight into the roles of disordered tumor vasculature and HIF1α- and VEGF…

nonrandomized-trial 2019
First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors
Clinical cancer research : an official journal of the American Association for Cancer Research ·doi:10.1158/1078-0432.ccr-19-1065

PURPOSE: STM 434 is a soluble receptor ligand trap targeting activin A, a protein in the TGFβ family that plays important roles in growth, differentiation, and cancer cachexia. This study evaluated the safety, antitumor activity, and metabo…